

DAFTAR PUSTAKA

- Acosta PE. (2018). *Antiviral agents (nonretroviral)*. In: Brunton LL, Hilal-Dandan R, Knollmann BJ, editors. *Goodman & Gilman's: the pharmacological basis of therapeutics* 13th ed. New York: McGraw-Hill Education. p. 1105–16.
- Allouche, A. (2012). *Software News and Updates Gabedit — A Graphical User Interface for Computational Chemistry Softwares*. *Journal of Computational Chemistry*, 32, 174–182. <https://doi.org/10.1002/jcc>
- Amirian ES, Levy JK. (2020). *Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses*. *One Health*. 2020;9:100128.
- ASHP. (2020). *Assessment of evidence for COVID-19-related treatments: Updated 5/21/2020*.
- Bala, V. C., & Kumar, P. (2020). *Review on COVID-19: Rise of SARS-CoV-2 Pandemic Outbreak*. *Borneo Journal of Pharmacy*, 3(Special-1), 103–120. <https://doi.org/10.33084/bjop.v3ispecial-1.1412>
- Brown AJ, Won JJ, Graham RL, Dinnon III KH, Sims AC, Feng JY, et al. (2019). *Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase*. *Antiviral Res*. 2019;169:104541.
- Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M et al. (2020). *A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19*. *The New England journal of medicine*.
- Choy KT, Wong AYL, Kaewpreedee P, Sia SF, Chen D, Hui KPY, et al. (2020). *Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro*. *Antivir Res*. 2020 Apr 3; 178 [Epub ahead of print]. PMID: 32251767 DOI: 10.1016/j.antiviral.2020.104786.
- Dong L, Hu S, Gao J. (2020). *Discovering drugs to treat coronavirus disease 2019 (COVID-19)*. *Drug Discov Ther*. 2020;14(1):58–60.
- Dou D, Revol R, Östbye H, Wang H, Daniels R. (2018). *Influenza A virus cell entry, replication, virion assembly and movement*. *Front Immunol*. 2018;9:1581.
- Elfiky, A.A. (2020). *Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study*. *Life Sciences*, 2020. 253: p. 117592.
- Furuta Y, Komeno T, Nakamura T. (2017). *Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase*. *Proc Jpn Acad Ser B Phys Biol Sci*. 2017;93(7):449–63.

- Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. (2020). *Hydroxychloroquine dan azithromycin sebagai pengobatan COVID-19: hasil uji klinis berukuran non-rando labelterbuka*. Agen Antimikrob Int J 2020; 105949. <https://doi.org/10.1016/j.ijantimicag.2020.105949>
- Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, et al. (2020). *The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2*. Nat Microbiol. DOI: 10.1038/s41564-020-0695-z
- Gordon CJ, Tshesnokov EP, Woolner E, Perry JK, Feng JYm, Porter DP et al. (2020). *Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency*. J Biol Chem. 2020 Apr 13 [Epub ahead of print]. PMID: 32284326 DOI: 10.1074/jbc.RA120.013679
- Jackson A, Hill A, Puls R, Else L, Amin J, Back D, et al. (2011). *Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers*. J Antimicrob Chemother. 2011;66(3):635–40.
- Khaerunnisa, S., Suhartini, Awaluddin, R. (2020). *Penelitian In Silico untuk Pemula*. Jawa Timur : Airlangga University Press.
- Khalili, J. S. (2020). *Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19*. Journal of Medical Virology.
- Kimia, P. S., Sains, F., & Palopo, U. C. (2016). *Penggunaan Aplikasi MarvinSketch*
- Laskowski, R. A., Jabłońska, J., Pravda, L., Vařeková, R. S., & Thornton, J. M. (2018). *PDBsum: Structural summaries of PDB entries*. Protein Science, 27(1), 129–134. <https://doi.org/10.1002/pro.3289>
- Lestari, Tresna. (2015). Jurnal Farmasi Indonesia. STIKes Bakti Tunas Husada. Taksimalaya.
- Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. (2020). *Hydroxychloroquine, turunan klorokuin yang kurang beracun, sama efektifnya dalam menghambat infeksi SARS-CoV-2 secara in vitro*. Diskov Sel 2020; 6:16. <https://doi.org/10.1038/s41421-020-0156-0>
- Lu H. (2020). *Drug treatment options for the 2019-new coronavirus (2019-nCoV)*. Biosci Trends. 2020;14:69–71. PMID: 31996494 DOI: 10.5582/bst.2020.01020
- Meng, X. -Y. (2012). *Molecular Docking A Powerful Approach for Structure-Based Drug Discovery*. Current Computer Aided-Drug Design, 146-157.
- Michalska, K., Kim, Y., Jedrzejczak, R., Maltseva, N. I., Stols, L., Endres, M., & Joachimiak, A. (2020). *Crystal structures of SARS-CoV-2 ADP-ribose phosphatase: From the apo form to ligand complexes*. IUCrJ, 7, 814–824.

<https://doi.org/10.1107/S2052252520009653>

- Narko Benny; Prasetiawati, Riska; Soni, Dang; Khairiyah, Faridhatul, T. P. (2017). *Studi Penambatan Molekul Senyawa dari Umbi Bawang Dayak (Eleutherine Palmifolia (L) Merr.) sebagai Obat Antikanker Serviks*. Jurnal Ilmiah Farmako Bahari, Vol 8, No 2 (2017): Jurnal Ilmiah Farmako Bahari, 1–14. <https://journal.uniga.ac.id/index.php/JFB/article/view/643>
- Nojomi, M., Yassin, Z., Keyvani, H., Makiani, M. J., Roham, M., Laali, A., Dehghan, N., Navaei, M., & Ranjbar, M. (2020). *Effect of Arbidol (Umifenovir) on COVID-19: a randomized controlled trial*. BMC Infectious Diseases, 20(1), 1–11. <https://doi.org/10.1186/s12879-020-05698-w>
- Permin H, Norn S, Kruse E, Kruse PR. (2016). *Sejarah kulit kayu Cinchona dalam treatment malaria*. Medicinhist Arbog.
- Purnomo Hari. (2011). *Kimia Komputasi : Molecular Docking PLANTS*. Yogyakarta : Pustaka Pelajar.
- Rose, P. W., Prlić, A., Altunkaya, A., Bi, C., Bradley, A. R., Christie, C. H., Di Costanzo, L., Duarte, J. M., Dutta, S., Feng, Z., Green, R. K., Goodsell, D. S., Hudson, B., Kalro, T., Lowe, R., Peisach, E., Randle, C., Rose, A. S., Shao, C., ... Burley, S. K. (2017). *The RCSB protein data bank: Integrative view of protein, gene and 3D structural information*. Nucleic Acids Research, 45(D1), D271–D281. <https://doi.org/10.1093/nar/gkw1000>
- Ruswanto Ruswanto, Nur Rahayuningsih Nur Laeli Dwi Hidayati Ginna Sri Nuryani, R. M. (2019). *Uji In Vitro dan Studi In Silico Senyawa Turunan N' -Benzoylisonicotinohydrazide sebagai Kandidat Antituberkulosis (In Vitro and In Silico Study of N' -Benzoylisonicotinohydrazide as Antituberculosis Candidate)*. 17(2), 218–226.
- Ruswanto, R. (2015). *Molecular Docking Empat Turunan Isonicotinohydrazide Pada Mycobacterium Tuberculosis Enoyl-Acyl Carrier Protein Reductase (InhA)*. Jurnal Kesehatan Bakti Tunas Husada: Jurnal Ilmu-Ilmu Keperawatan, Analis Kesehatan Dan Farmasi, 13(1), 135–141. <https://doi.org/10.36465/jkbth.v13i1.25>
- Ruswanto, R., Ratnasari, A., & Tuslinah, L. (2015). *Sintesis Senyawa N'-(3,5-Dinitrobenzoyl)-Isonicotinohydrazide dan Studi Interaksinya pada Mycobacterium tuberculosis Enoyl Acyl Carrier Protein Reductase (INH A)*. Jurnal Kesehatan Bakti Tunas Husada: Jurnal Ilmu-Ilmu Keperawatan, Analis Kesehatan Dan Farmasi, 14(1), 63. <https://doi.org/10.36465/jkbth.v14i1.112>
- Sari, I.W., Junaidin, Pratiwi, D. (2020). *Studi Molecular Docking Senyawa Flavonoid Herba Kumis Kucing (Orthosiphon stamineus B.) pada Reseptor α -Glukosidase sebagai Antidiabetes Tipe 2*. Sekolah Tinggi Farmasi Muhammadiyah Tangerang. <http://dx.doi.org/10.47653/farm.v7i2.194>.
- Sissoko D, Laouenan C, Folkesson E, M'Lebing AB, Beavogui AH, Baize S, et al. (2016). *Experimental treatment with favipiravir for Ebola virus disease (The*

- JIKI Trial*): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med. 2016;13(3):e1001967.
- Treatment Plan Edition 5. (2020). www.gov.cn/zhengce/zhengceku/2020-02/05/5474791/files/de44557832ad4be1929091dcbcfca891.pdf. Diakses 5 Februari 2020.
- Schrezenmeier E, Dorner T. (2020). *Mekanisme aksi dari hydroxychloroquine dan klorokuin: implikasi untuk rematik*. Nat Rev Rheumatol 2020; 16(3):155-66. <https://doi.org/10.1038/s41584-020-0372-x>
- Susilo, A., Rumende, C. M., Pitoyo, C. W., Santoso, W. D., Yulianti, M., Herikurniawan, H., Sinto, R., Singh, G., Nainggolan, L., Nelwan, E. J., Chen, L. K., Widhani, A., Wijaya, E., Wicaksana, B., Maksum, M., Annisa, F., Jasirwan, C. O. M., & Yuniastuti, E. (2020). *Coronavirus Disease 2019: Tinjauan Literatur Terkini*. Jurnal Penyakit Dalam Indonesia, 7(1), 45. <https://doi.org/10.7454/jpdi.v7i1.415>
- Williamson BN, Feldmann F, Schwarz B, Meade-White K, Porter DP, Schulz J, et al. (2020). *Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2*. Preprint. (not peer reviewed). <https://doi.org/10.1101/2020.04.15.043166>.
- Wishart, D. S., Knox, C., Guo, A. C., Shrivastava, S., Hassanali, M., Stothard, P., Chang, Z., & Woolsey, J. (2006). *DrugBank: a comprehensive resource for in silico drug discovery and exploration*. Nucleic Acids Research, 34(Database issue), 668–672. <https://doi.org/10.1093/nar/gkj067>
- WHO. (2020). *COVID-19 Weekly Epidemiological Update*. November, 1;4. <https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201012-weekly-epi-update-9.pdf>
- Yuliana, A., Fitriaji S P, H., Siti Mukhaufillah, K., & Rahmawati Rizkuloh, L. (2020). *In Silico Study on Testing Antidiabetic Compounds Candidate from Azaphilone Monascus sp.* Microbiology Indonesia, 14(2), 52–65. <https://doi.org/10.5454/mi.14.2.2>
- Zhou D, Dai SM, Tong Q. (2020). *COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression*. J Antimicrob Chemother. 2020;75(7):1667–70.